RZLT - Rezolute, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$8.67
DETAILS
HIGH:
$14.00
LOW:
$6.00
MEDIAN:
$6.00
CONSENSUS:
$8.67
UPSIDE:
105.45%
About Rezolute, Inc. (https://www.rezolutebio.com)
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Nevan Charles Elam | Founder, Chief Executive Officer, Principal Financial Officer & Acting Chairman of the Board | 1967 | $1,083,905 USD |
| Brian Kenneth Roberts | Chief Medical Officer | 1976 | $767,526 USD |
| Daron G. Evans | Chief Financial & Business Officer | 1974 | $699,209 USD |
| Chris Milks | Vice President & Head of Finance | – | – |
| Davelyn Eaves Hood | Director and Head of Scientific & Patient Affairs | – | – |
| Melissa Quinn | Senior Director of People and Culture | – | – |
| Michael Covarrubias | Senior Vice President & Head of Program & Portfolio Management | – | – |
| Michael R. Deperro | Senior VP & Head of Operations | – | – |
| Raj Agrawal | Vice President & Head of Ophthalmological Clinical Development | – | – |
| Robyn Sweinhart | Vice President & Head of Quality | – | – |